Twist Bioscience (TWST) Gets a Buy from Scotiabank

Scotiabank analyst Sung Ji Nam maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $48.00. The company’s shares closed last Friday at $41.21.

According to TipRanks, Ji Nam is an analyst with an average return of -4.2% and a 45.21% success rate. Ji Nam covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Bio-Techne, and Quanterix.

In addition to Scotiabank, Twist Bioscience also received a Buy from TD Cowen’s Steven Mah in a report issued on May 3. However, on the same day, J.P. Morgan maintained a Sell rating on Twist Bioscience (NASDAQ: TWST).

TWST market cap is currently $2.4B and has a P/E ratio of -12.31.

Based on the recent corporate insider activity of 124 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TWST in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Twist Bioscience (TWST) Company Description:

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The company also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. Twist Bioscience was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.